China SXT Pharmaceuticals, Inc.
SXTC
$2.61
-$0.02-0.76%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.45% | -24.45% | -7.85% | -7.85% | -11.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.45% | -24.45% | -7.85% | -7.85% | -11.73% |
| Cost of Revenue | -24.47% | -24.47% | -6.14% | -6.14% | 6.70% |
| Gross Profit | -24.48% | -24.48% | -12.42% | -12.42% | -53.26% |
| SG&A Expenses | 733.20% | 733.20% | 132.54% | 132.54% | -91.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 374.55% | 374.55% | 147.12% | 147.12% | -85.73% |
| Operating Income | -893.26% | -893.26% | -128.14% | -128.14% | 93.17% |
| Income Before Tax | -693.52% | -693.52% | -137.91% | -137.91% | 91.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -693.52% | -693.52% | -137.91% | -137.91% | 91.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -693.52% | -693.52% | -137.91% | -137.91% | 91.72% |
| EBIT | -893.26% | -893.26% | -128.14% | -128.14% | 93.17% |
| EBITDA | -1,006.84% | -1,006.84% | -127.57% | -127.57% | 93.84% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |